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Background: Subclinical thyroid dysfunction is common among older people and has been associated with
decreased functional capacity but with conflicting data. The aim of this study was to assess the association
between subclinical thyroid dysfunction and functional capacity in an elderly population.
Methods:We included 5182 participants with a mean age of 75.2 years from the Prospective Study of Pravastatin
in the Elderly at Risk (PROSPER). Self-reported functional capacity was assessed using the Barthel Index (BI) and
the Instrumental Activities of Daily Living (IADL) scores at baseline and during follow-up. Participants with
subclinical hyperthyroidism (n= 65) and subclinical hypothyroidism (n = 173) were compared to euthyroid
participants (n = 4944). The association between persistent subclinical thyroid dysfunction and functional ca-
pacity and decline was also investigated.
Results: At baseline, compared to euthyroid participants (BI 19.73 – SE 0.06; IADL 13.52 – 0.02), there was no
difference in functional capacity for participants with subclinical hyperthyroidism (BI 19.60 – 0.09; IADL
13.51 – 0.12, p > 0.05) or subclinical hypothyroidism (BI 19.82 – 0.06; IADL 13.55 – 0.08, p > 0.05). Over a mean 3.2-
year follow-up period, there was no association between thyroid function and annual decline of either BI or
IADL ( p > 0.05). No association was found between persistent subclinical thyroid dysfunction and functional
capacity at baseline or during follow-up ( p > 0.05). Results were similar after excluding participants with a
maximum BI and/or IADL score at baseline.
Conclusion: Among well-functioning community-dwelling elderly, we found no evidence that subclinical thy-
roid dysfunction contributes to decreased functional capacity.
Introduction
Subclinical thyroid dysfunction is a common condi-tion, particularly among older people (1–3). It is defined
as a biochemical perturbation of thyrotropin (TSH) values
with normal free T4 levels (1,3,4), irrespective of the presence
or absence of symptoms (3,5,6). The prevalence of subclinical
thyroid dysfunction increases with age, reaching up to 4% for
subclinical hyperthyroidism (1–3) and up to 20% for sub-
clinical hypothyroidism in subjects older than 65 years of age
(1,3,7).
Subclinical thyroid dysfunction has been associated with
several adverse outcomes, such as cardiovascular disease (8–
10), osteoporosis (1,11–13), and cognitive dysfunction
(6,14,15). Furthermore, subclinical thyroid dysfunction has
also been associated with decreased functional capacity (16)
and neuromuscular abnormalities (17), but data are conflict-
ing (17–20), and reliable evidence on the association between
subclinical thyroid dysfunction and functional capacity in an
older population is lacking.
Both subclinical hyperthyroidism and subclinical hypo-
thyroidism may progress to overt disease or revert to
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euthyroidism in the course of months (21). Studies with re-
peated TSH measurements, which can identify persistent
thyroid dysfunction, may be more strongly associated with
specific endpoints than studies with a single measurement of
TSH. To date, there are no data on the association between
persistent subclinical thyroid dysfunction and functional
capacity.
Therefore, we assessed the association between subclinical
thyroid dysfunction and functional capacity in the Pro-
spective Study of Pravastatin in the Elderly at Risk (PROS-
PER) (22). In more than 5000 participants, we investigated the
association between thyroid status at baseline and persistent
thyroid status after six months, and repeated assessments of
functional capacity during a mean 3.2-year follow-up period.
Methods
Subjects
All subjects were participants of the PROSPER trial,
designed to assess if pravastatin would reduce the risk of
cardiovascular events in an elderly population with cardio-
vascular disease or at high risk of developing cardiovascular
disease. Details on the study design have been previously
described (23). A total of 5804 men and women aged 70–82
years with pre-existing cardiovascular disease (including
coronary, cerebrovascular, or peripheral artery disease) or at
risk to develop such a condition (current cigarette smoking,
hypertension, known diabetes mellitus, or fasting blood glu-
cose >7mmol/L) were randomized to receive either pra-
vastatin 40mg daily or placebo over amean 3.2-year period in
Scotland, Ireland, and the Netherlands. Participants with
congestive heart failure (New York Heart Association III or
IV), physical or mental inability to attend the clinic for the
screening visit, or poor cognitive function (Mini Mental Score
Examination < 24 points) were excluded from the PROSPER
trial.
From the initial trial population, we excluded participants
with missing TSH and/or free T4 levels and with missing
Barthel Index (BI) or Instrumental Activities of Daily Living
(IADL) scores. Participants using antithyroid medication
and/or thyroxine supplementation were also excluded. The
trial protocol was approved by the Medical Ethic Committees
of all involved centers, and all participants provided written
informed consent.
Thyroid function
TSH was measured at baseline in all participants. Mea-
surements were performed in three respective laboratory
centers (Glasgow in theUnitedKingdom, Cork in Ireland, and
Leiden in the Netherlands). Indications for additional mea-
surements of free T4 were different between countries. In
Scotland and Ireland, free T4 levels weremeasuredwhen TSH
was abnormal based upon specific cutoff levels of TSH (when
TSH was < 0.45 or >10mIU/L in Scotland, and < 0.3 or
>5mIU/L in Ireland), while they were measured in all par-
ticipants in the Netherlands, independently of the TSH result.
TSH and free T4 levels were measured using state-of-the-
art immunoassays (third-generation assays with a functional
sensitivity £ 0.05mIU/L). For both measurements, estimated
inter- and intra-assay coefficients of variation were less than
5%. Both TSH and free T4 levels were measured again at six
months of follow-up in available frozen plasma samples of
all participants, which were stored at the University of Glas-
gow. The same electrochemiluminescence immunodetection
method on a Roche Elecsys 2010 (Burgess Hill, United King-
dom) was used. The limits of detection were < 0.005mIU/L
for TSH and 0.3 pmol/L for free T4 (reference range: 12–
22 pmol/L). A reference range between 0.45 and 4.50mIU/L
derived from relevant literature was used for TSH (4,9). The
narrowest free T4 reference range (12–18 pmol/L) was chosen
to take interlaboratory differences into account (24).
On the basis of previous publications (4,25–28), we classi-
fied participants into three thyroid states groups. At base-
line, subclinical hypothyroidism was defined as TSH
levels ‡ 4.5mIU/L with normal free T4 levels. Subclinical
hyperthyroidism was defined as TSH levels £ 0.45mIU/L
with normal free T4 levels. Participants with normal TSH
levels (0.45–4.5mIU/L) were considered euthyroid. At six
months, we used the same classification to define subclinical
thyroid status. Participants with the same condition at base-
line and after six months were defined as having persistent
subclinical hypothyroidism, persistent subclinical hyperthy-
roidism, or persistent euthyroidism. Based on previous
studies (4,8,9,24,26,28) and expert reviews (4,27), we further
stratified our analyses for other TSH ranges (TSH < 0.1, TSH
0.1–0.45, TSH 4.5–10, and TSH >10mIU/L).
Functional capacity
Functional capacity was measured using two question-
naires: the BI and the IADL. Both questionnaires have previ-
ously been proven to be sensitive to detect changes in an
elderly population (29,30). The measurements were per-
formed at baseline; after 9, 18, and 30 months; and at the end
of the study, which varied between 36 and 42 months.
The BI is a common questionnaire used to assess self-care
activities of daily living and level of dependence of an indi-
vidual (31). The BI consists of 10 items, in which fecal and
urinary continence, grooming, toilet use, feeding, transfers
(e.g., from chair to bed), walking, dressing, climbing stairs,
and bathing are scored. The maximum score of the BI is 20
points; a higher score represents higher independence and
mobility, that is, higher functional capacity.
The IADL questionnaire also measures activities of daily
living, but involves interaction with the physical and social
environment (32), and is therefore questioning about more
complex tasks compared to the BI. The questionnaire includes
seven items, including housework, taking medication as
prescribed, managing money, shopping for groceries or
clothing, use of telephone or other form of communication,
using technology, and transportation within the community.
The maximum score of the IADL is 14 points; a higher score
also means higher independence and mobility in both indoor
and outdoor environment, that is, higher functional capacity.
Statistical analyses
Baseline characteristics are reported in three thyroid sub-
groups, according to thyroid status. t-Tests and chi-square
tests were used to compare participants with subclinical
thyroid dysfunction to euthyroid participants. We performed
linear regression analyses to assess the cross-sectional asso-
ciation between subclinical thyroid status and functional ca-
pacity. Adjustments were made for age, sex, country, history
SUBCLINICAL THYROID FUNCTION AND FUNCTIONAL CAPACITY 209
of vascular disease, history of diabetes, history of hyperten-
sion, and current smoking.
Since treatment with pravastatin did not affect functional
capacity (22), we combined data from both groups to inves-
tigate the association between subclinical thyroid dysfunction
and functional decline. For this longitudinal association, we
used linear mixed models, which included baseline thyroid
status or persistent thyroid status, time (in years), and the
interaction term between time and baseline thyroid status or
persistent thyroid status. The dependent variable was the
score on BI and IADL questionnaires. The change in func-
tional capacity per year for each groupwas represented by the
estimated value for annual change over time. Models were
adjusted for age, sex, country, statin treatment, history of
vascular disease, history of diabetes, history of hypertension,
and current smoking.
Additionally, we further performed analyses in which we
(i) investigated participants with suppressed or elevated TSH
levels (TSH < 0.1 or TSH >10mIU/L); (ii) included TSH levels
as a continuous variable in our analyses; (iii) stratified the
analyses by cardiovascular disease and risk factors to inves-
tigate their potential confounding effect; (iv) excluded par-
ticipants with a maximum BI and/or IADL score at baseline;
(v) stratified the longitudinal analyses by treatment group;
and (vi) used a wider free T4 range, with 10.3–25.7 pmol/L
considered normal according to relevant literature (4,33). Fi-
nally, since we previously reported that subclinical hypo-
thyroidismwith TSH levels >10mIU/Lwas associatedwith a
higher rate of heart failure in PROSPER (24), a decreased level
of functional capacity among those participants is expected.
Therefore, we further investigated whether excluding these
participants from the analyses changed our results.
p-Values below 0.05 were considered statistically signifi-
cant. All analyses were conducted using SPSS (v20.0; PASW
Statistics Inc., Chicago, IL).
Results
Baseline characteristics
From the initial study population of 5804 participants, 8
individuals with missing TSH values, 303with abnormal TSH
and unknown free T4 values, 136 with overt thyroid disease,
and 1withmissing BI and IADL scores were excluded (Fig. 1).
Six participants taking antithyroid medication and 160 par-
ticipants using thyroxine supplementation were excluded.
The final sample of our study was therefore 5182 participants.
The mean age of the study population was 75.3 years
(standard deviation [SD] 3.3 years; Table 1). A total of 65
participants had subclinical hyperthyroidism. In line with our
expectation, this condition was more common in women
(73.8%) than in men. Subclinical hypothyroidism was found
in 173 participants, and 64.2% were women. Groups were
similar on most variables, except for body mass index (BMI)
and hypertension. Subclinical hyperthyroidism was associ-
ated with lower BMIwhen compared to euthyroid participants
(25.7vs. 26.8; p= 0.03). The prevalence of hypertension was
higher in participants with subclinical hypothyroidism com-
pared to those with euthyroidism (68.2% vs. 61.0%; p= 0.02).
Baseline thyroid status and functional capacity
At baseline, the overall mean BI and IADL scores were high
(19.71 and 13.53 points respectively) with a range of 11–20
points for the BI and 4–14 points for the IADL (Table 2). The
FIG. 1. Flowchart of study
participants. TSH, thyro-
tropin; FT4, free thyroxine;
BI, Barthel Index; IADL,
Instrumental Activities of
Daily Living.
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mean score on BI and IADL did not differ among participants
with subclinical hyperthyroidism and subclinical hypothy-
roidism compared to euthyroid participants ( p > 0.05). Al-
though a significant decrease in functional capacity over the
3.2-year follow-up time was observed for both BI and IADL
( - 0.09 and - 0.16 points per year respectively; p < 0.001),
there was no difference in annual decline of BI or IADL when
comparing participants with subclinical thyroid dysfunction
to euthyroid participants ( p> 0.05). The results did not ma-
terially change after (i) investigation of potential differences
within TSH subgroups (TSH < 0.1 and TSH >10mIU/L); (ii)
analysis of TSH as a continuous variable; (iii) stratification by
presence or absence of cardiovascular disease at baseline; (iv)
exclusion of participants with a maximal BI and/or IADL
score at baseline; (v) stratification by treatment group; and (vi)
using a wider free T4 range (data not shown). Furthermore,
we found that participants with incident heart failure hospi-
talization (n= 235) had a significant decrease in both BI and
IADL over the 3.2-year follow-up time (- 0.31 and - 0.51
points per year respectively; p< 0.001), but excluding these
participants did not change the results.
Persistent thyroid status and functional capacity
Among the 65 participants with subclinical hyperthyroid-
ism at baseline, 41 still had subclinical hyperthyroidism after
six months and were defined as having persistent subclinical
hyperthyroidism. Among the 173 participants with subclini-
cal hypothyroidism at baseline, 93 had subclinical hypothy-
roidism at six months and were defined as having persistent
subclinical hypothyroidism. After exclusion of participants
with changing thyroid status, there were no differences in
functional capacity between groups with persistent thyroid
status at sixmonths (Table 3; p> 0.05). No association between
Table 1. Baseline Characteristics of Study Participants Depending on Thyroid Status
Thyroid status p-Value for difference
All
(N = 5182)
Subclinical
hyperthyroidism
(n = 65)
Euthyroidism
(n = 4944)
Subclinical
hypothyroidism
(n = 173)
Subclinical
hyperthyroidism
vs. euthyroidism
Subclinical
hypothyroidism
vs. euthyroidism
Demographics
Female, n (%) 2556 (49.3%) 48 (73.8%) 2397 (48.5%) 111 (64.2%) < 0.001 < 0.001
Age (years), mean – SD 75.3 – 3.3 75.3 – 0.4 75.3 – 0.1 75.6 – 0.3 0.91 0.20
Education (age left
school), mean – SD
15.1 – 2.1 15.3 – 0.3 15.1 – 0.0 15.2 – 0.2 0.56 0.84
Biometrics, mean – SEa
Weight (kg) 73.5 – 0.2 71.7 – 1.5 73.5 – 0.2 75.2 – 0.9 0.26 0.07
Height (cm) 165.5– 0.1 166.6– 0.8 165.4– 0.1 166.6– 0.5 0.15 0.02
BMI (kg/m2) 26.8 – 0.1 25.7 – 0.5 26.8 – 0.1 27.0 – 0.3 0.03 0.48
SBP (mmHg) 154.7– 0.3 153.8– 2.7 154.6– 0.3 157.0– 1.7 0.77 0.16
DBP (mmHg) 83.9 – 0.2 82.6 – 1.4 83.9 – 0.2 84.4 – 0.9 0.38 0.53
Cardiovascular risk factors, n (%)
Current smoker 1422 (27.4%) 12 (18.5%) 1371 (27.7%) 39 (22.5%) 0.14 0.08
History of diabetes 561 (10.8%) 10 (15.4%) 526 (10.6%) 25 (14.5%) 0.25 0.20
History of hypertension 3173 (61.2%) 38 (58.5%) 3017 (61.0%) 118 (68.2%) 0.61 0.02
History of vascular
disease
2293 (44.2%) 26 (40.0%) 2190 (44.3%) 77 (44.5%) 0.51 0.84
History of TIA/stroke 585 (11.3%) 6 (9.2) 556 (11.2%) 23 (13.3%) 0.56 0.94
aAdjusted for age and sex.
N, number; SD, standard deviation; SE, standard error; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;
TIA, transient ischemic attack.
Table 2. Functional Capacity and Decline Depending on Thyroid Status at Baseline
Thyroid status p-Value for difference
Functional capacity,
mean – SE
All
(N = 5182)
Subclinical
hyperthyroidism
(n = 65)
Euthyroidism
(n = 4944)
Subclinical
hypothyroidism
(n = 173)
Subclinical
hyperthyroidism
vs. euthyroidism
Subclinical
hypothyroidism
vs. euthyroidism
Barthel Index, range 11–20 15–20 11–20 15–20
Baseline score 19.71 – 0.04 19.60– 0.09 19.73 – 0.06 19.82– 0.06 0.147 0.103
Annual change - 0.09 – 0.00 - 0.08 – 0.03 - 0.09 – 0.00 - 0.09 – 0.02 0.859 0.952
IADL, range 4–14 10–14 4–14 7–14
Baseline score 13.53 – 0.05 13.51– 0.12 13.52 – 0.02 13.55– 0.08 0.910 0.721
Annual change - 0.16 – 0.01 - 0.23 – 0.05 - 0.16 – 0.01 - 0.14 – 0.03 0.144 0.641
Data represent mean – SE. Adjusted for age, sex, country, history of vascular diseases, history of hypertension, history of diabetes mellitus,
current smoking, and additionally for statin treatment in the longitudinal analyses.
IADL, Instrumental Activities for Daily Living.
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persistent thyroid status and functional decline over time
was observed ( p > 0.05).
Discussion
In this large prospective cohort study of more than 5000
older persons, including an analysis with persistent subclini-
cal thyroid dysfunction, we found no consistent association
between subclinical thyroid dysfunction and self-reported
functional capacity or decline in old age.
Previously, few studies evaluated the relationship between
subclinical thyroid dysfunction and functional capacity, with
conflicting results. A cross-sectional study that included 42
participants with subclinical hypothyroidism found no asso-
ciation with functional capacity as measured by the Bruce
treadmill (17). Similarly, the Leiden 85-Plus Study, a popu-
lation-based study, showed that subclinical thyroid dysfunc-
tion was not associated with functional capacity in 558
participants from the age of 85 years onwards (18). Simonsick
et al. showed that people between 70 and 79 years of age did
not have more frequent mobility problems (20). In this study,
individuals with amild elevation in TSH levels (4.5–7mIU/L)
had a faster mean usual and rapid gait speed and better car-
diorespiratory fitness and reported walking ease. Portella
et al. reported that subclinical hyperthyroidism was not as-
sociated with changes in exercise performance in young
female adults (19). This experimental study included only 14
participants with well-differentiated thyroid carcinoma on
suppressive levothyroxine therapy leading to subclinical
hypothyroidism, and assessed exercise capacity by using the
treadmill cardiopulmonary test. Furthermore, a randomized
study demonstrated that exercise performance was improved
in individuals with subclinical hypothyroidism treated with
levothyroxine after six months of TSH normalization (16).
According to several hypotheses, we expected to find an
association between subclinical thyroid status and functional
capacity. First, as subclinical thyroid dysfunction has been
associated with cardiovascular disease (8–10), we hypothe-
sized a decline in functional capacity in those with subclinical
thyroid status due to a higher rate of cardiovascular events,
such as stroke or myocardial infarction (24). Second, literature
shows that individuals with both subclinical and overt thy-
roid conditions have more frequent musculoskeletal symp-
toms. An experimental study demonstrated that higher free
T4 concentrations were associated with decreased physical
performance and muscle strength, independently of TSH
levels (34). A cross-sectional study including 137 participants
showed that Dupuytren’s contracture, limited joint mobility,
and carpal tunnel syndromewere significantly more common
among middle-aged subjects with hypothyroidism (35).
Moreover, subclinical hyperthyroidism and overt hyperthy-
roidism have also been associated with increased risk of os-
teoporosis (1,11–13), which could also contribute to impaired
functional capacity. Therefore, we expected that similar
manifestations could be observed in subclinical thyroid states,
leading to decline of functional capacity. Finally, as subclinical
thyroid dysfunction has been linked to adverse cognitive
outcomes (6,14,15), we assumed that functional capacity
could be impaired in individuals with subclinical thyroid
dysfunction due to additional cognitive decline.
The fact that we did not find any association between
subclinical thyroid dysfunction and changes in functional
capacity could be explained by two main reasons. The first is
that the hypothesized biological relation does not exist. So far,
only one study investigated muscle metabolism and exercise
tolerance impairments as possible biological mechanisms in-
volved in subclinical hypothyroidism (36). Muscle metabo-
lism has also been suggested to be impaired in Hashimoto’s
hypothyroidmyopathy (37). The few other positive studies on
the association between subclinical thyroid dysfunction and
functional capacity did not clearly report which biological
mechanisms could be involved (16,17). Second, the partici-
pants in the PROSPER study were excluded at baseline if they
had poor cognitive function (Mini Mental Score Examination
< 24/30 points) or if they were physically or mentally unable
to attend the clinic for the screening visit (23). Therefore, the
population in this study excluded elderly with functional and
cognitive impairment, potentially leading to reduced power
to detect changes in functional capacity. However, we did
observe a significant decline in functional capacity among all
participants (n = 5182) and in a small subgroup analysis
(n= 235), suggesting that our measurements were sensitive
enough to detect functional decline. Although the rate of
spontaneous normalization of TSH levels in subclinical thy-
roid disorders can be as high as 65%, studies evaluating per-
sistent subclinical thyroid dysfunction are rare (38,39). The
fact that we have data on persistence of subclinical thyroid
dysfunction, which is the most robust reflection of subclinical
Table 3. Functional Capacity and Decline Depending on Persistent Thyroid Status
Persistent thyroid status p-Value for difference
Functional capacity,
mean –SE
All
(N= 4593)
Subclinical
hyperthyroidism
(n = 41)
Euthyroidism
(n = 4459)
Subclinical
hypothyroidism
(n = 93)
Subclinical
hyperthyroidism
vs. euthyroidism
Subclinical
hypothyroidism
vs. euthyroidism
Barthel Index, range 11–20 15–20 11–20 18–20
Baseline score 19.73– 0.05 19.59– 0.11 19.74– 0.02 19.85 – 0.07 0.161 0.151
Annual change - 0.08 – 0.00 - 0.04 – 0.04 - 0.08 – 0.0 - 0.09 – 0.03 0.486 0.807
IADL, range 4–14 10–14 4–14 7–14
Baseline score 13.52– 0.06 13.43– 0.15 13.53– 0.03 13.60 – 0.10 0.477 0.527
Annual change - 0.15 – 0.01 - 0.19 – 0.06 - 0.15 – 0.01 - 0.12 – 0.04 0.536 0.444
Data represent mean– SE. Adjusted for age, sex, country, history of vascular diseases, history of hypertension, history of diabetes mellitus,
current smoking and additionally for statin treatment in the longitudinal analyses.
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thyroid status and a limitation of several previous studies,
together with repeated measurements of functional capacity
increased our power to detect a potential association and a
decline in functional capacity over time. Moreover, the large
sample size of our study and the overall high prevalence of
subclinical thyroid dysfunction increased the power to detect
an association between subclinical thyroid conditions and
functional capacity.
There are several limitations in our study. First, the studied
population had a good functional capacity at baseline.
Therefore, our findings are only generalizable to a high
functioning population. Second, the 3.2-year follow-up period
could have limited the power to detect changes in functional
capacity among our population. A longer follow-up period
might be needed to find changes in functional capacity. Fur-
thermore, only two self-reporting questionnaires to assess
functional capacity were used, which might be insensible to
detect changes. However, it has recently been shown that
subclinical thyroid dysfunction was not associated with cog-
nitive performance or decline in the present population (33).
Although cognitive decline has been reported for many de-
terminants in the studied population (40–42), the absence of
such association between subclinical thyroid dysfunction and
cognitive decline further strengthens the findings of our an-
alyses, which shows no association with functional capacity
or decline. Finally, as indications for free T4 measurements
differed for each country, this could have resulted in some
differences between the participants in Scotland, Ireland, or
the Netherlands. However, free T4 was measured in all par-
ticipants with TSH >10mIU/L, a group in which we also did
not find a significant association.
In conclusion, there is no evidence to support a relationship
between subclinical thyroid dysfunction and functional ca-
pacity in a large population of well-functioning community-
dwelling older people.
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